Roche ’s Tecentriq becomes the first subcutaneous anti-PD-(L)1 cancer immunotherapy available to patients in Great Britain, reducing treatment time to just minutes
Tecentriq subcutaneous (SC) is now approved in Great Britain for all indications of intravenousTecentriq, including certain types of lung, bladder, breast and liver cancer, offering a faster, more convenient option to receive treatmentAdministered under the skin within approx. seven minutes,Tecentriq SC saves time for patients and helps conserve resources in healthcare systems1Evaluations by the FDA, EMA and other health authorities globally are ongoingBasel, 29 August 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that Tecentriq ® SC (atezolizumab) has been approved by the Medicines and Healthcare products Reg...
Source: Roche Media News - August 29, 2023 Category: Pharmaceuticals Source Type: news
Low Recurrence Seen With Omission of Radiation in Some Breast Cancer Cases
THURSDAY, Aug. 17, 2023 -- The incidence of local recurrence at five years is low among women aged at least 55 years with T1N0, grade 1 or 2, luminal A breast cancer who were treated with breast-conserving surgery and endocrine therapy without... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - August 17, 2023 Category: Pharmaceuticals Source Type: news
Skipping Radiation May Be Safe for Some With Early Breast Cancer
THURSDAY, Aug. 17, 2023 -- Many women with early breast cancer undergo breast-conserving surgery along with radiation to kill any errant cancer cells, but some may be able to safely skip radiation, new research suggests. “If the tumors are... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - August 17, 2023 Category: General Medicine Source Type: news
Breast-Conservation Therapy Feasible in Multiple Ipsilateral Breast Cancer
WEDNESDAY, April 12, 2023 -- For women with multiple ipsilateral breast cancer, breast-conserving therapy (BCT) with adjuvant radiation results in a low five-year local recurrence rate, according to a study published online March 28 in the Journal... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - April 12, 2023 Category: Pharmaceuticals Source Type: news
Breast Conservation Safe Even With Multiple-Site Tumors Breast Conservation Safe Even With Multiple-Site Tumors
New research adds important prospective data showing low recurrence rates with breast conservation even among patients with multiple ipsilateral breast cancer.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - March 28, 2023 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
News at a glance: Monkey shipments, a controversial visa, and support for geoengineering research
ANIMAL RESEARCH
Lab pauses monkey imports
Charles River Laboratories, one of the largest U.S. importers and suppliers of research monkeys, announced last week it is suspending shipments from Cambodia after receiving a subpoena from the U.S. Department of Justice. In November 2022, the agency indicted members of a smuggling ring that was illegally exporting cynomolgus macaques caught in the wild in Cambodia, labeling them as captive-bred. Charles River said the subpoena is related to several shipments it received from its Cambodian supplier. Charles River said the suspension was voluntary and motivate...
Source: ScienceNOW - March 2, 2023 Category: Science Source Type: news
Omission of Radiotherapy After Breast-Conserving Surgery Explored
THURSDAY, Feb. 16, 2023 -- For women with hormone receptor-positive, node-negative, T1 or T2 primary breast cancer undergoing breast-conserving surgery, omission of radiotherapy is associated with an increased incidence of local recurrence but has... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - February 16, 2023 Category: Pharmaceuticals Source Type: news
Safe to Omit RT After Lumpectomy in Certain Older Breast Cancer Patients
(MedPage Today) -- Radiotherapy after breast-conserving surgery can be safely omitted in certain older women with low-risk, hormone receptor-positive early breast cancer receiving adjuvant endocrine therapy, 10-year results of the PRIME II trial... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - February 15, 2023 Category: Hematology Source Type: news
Genomic Assay May Pinpoint Who Can Skip RT After Breast-Conserving Surgery
(MedPage Today) -- An investigational genomic assay may be able to identify women who don't stand to benefit from adjuvant radiation therapy (RT) following breast-conserving surgery, researchers reported.
Using tumor samples from a completed phase... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - January 6, 2023 Category: Hematology Source Type: news
Breast Conservation Safe Option in Multisite Breast Cancer Breast Conservation Safe Option in Multisite Breast Cancer
Eagerly awaited results show for the first time, from a prospective trial, that women with multiple breast cancer foci can safely undergo breast-conserving therapy, with low local recurrence rates.Medscape Medical News (Source: Medscape General Surgery Headlines)
Source: Medscape General Surgery Headlines - December 12, 2022 Category: Surgery Tags: Hematology-Oncology News Source Type: news
Better Imaging Allows More Women to Opt for Breast - Conserving Surgery
(Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - December 9, 2022 Category: Cancer & Oncology Tags: Oncology, Radiology, Surgery, News, Source Type: news
Better Imaging Allows More Women to Opt for Breast-Conserving Surgery
FRIDAY, Dec. 9, 2022 -- Mastectomy has long been the standard of care for certain breast cancer patients, but it still may be more extensive than many women need, a new study suggests.
Researchers found that many women who have two or even three... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - December 9, 2022 Category: General Medicine Source Type: news
Gene Test Might Help Some Breast Cancer Patients Skip Radiation After Lumpectomy
FRIDAY, Dec. 9, 2022 -- A new genetic test may help determine which people with breast cancer can safely skip radiation after breast-conserving surgery to remove their tumor.
Individuals with invasive breast cancer who had low scores on an... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - December 9, 2022 Category: General Medicine Source Type: news
Benefits of RT After Breast - Conserving Surgery Only Seen Within 10 Years
Findings seen at 30 - year follow - up of patients who underwent breast - conserving surgery, systemic therapy for early - stage breast cancer (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - December 8, 2022 Category: Cancer & Oncology Tags: Gynecology, Oncology, Radiology, Surgery, Conference News, Source Type: news
Benefits of RT After Breast-Conserving Surgery Only Seen Within 10 Years
THURSDAY, Dec. 8, 2022 -- The benefits of radiotherapy following breast-conserving surgery and systemic therapy for breast cancer in terms of fewer local recurrences are only seen during the first 10 years, with 30-year local recurrence and overall... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - December 8, 2022 Category: Pharmaceuticals Source Type: news
